{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T02:34:08Z","timestamp":1783564448309,"version":"3.55.0"},"reference-count":36,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.7038","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:00:57Z","timestamp":1649934057000},"page":"e227038","source":"Crossref","is-referenced-by-count":28,"title":["Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records"],"prefix":"10.1001","volume":"5","author":[{"given":"Michiel J. M.","family":"Niesen","sequence":"first","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Pawlowski","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"O\u2019Horo","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"},{"name":"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug W.","family":"Challener","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eli","family":"Silvert","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Donadio","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J.","family":"Lenehan","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abinash","family":"Virk","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie D.","family":"Swift","sequence":"additional","affiliation":[{"name":"Division of Preventive, Occupational and Aerospace Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh L.","family":"Speicher","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel E.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, Mayo Clinic Health System, Mankato, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Geyer","sequence":"additional","affiliation":[{"name":"Division of Hospital Internal Medicine, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Halamka","sequence":"additional","affiliation":[{"name":"Mayo Clinic Platform, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"Venkatakrishnan","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venky","family":"Soundararajan","sequence":"additional","affiliation":[{"name":"nference, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D.","family":"Badley","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota"},{"name":"Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"issue":"27","key":"zoi220221r1","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine.","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi220221r2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine.","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi220221r3","first-page":"979","article-title":"FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system.","volume":"2","author":"Pawlowski","year":"2021","journal-title":"Med (N Y)"},{"issue":"13","key":"zoi220221r4","doi-asserted-by":"publisher","first-page":"495","DOI":"10.15585\/mmwr.mm7013e3","article-title":"Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers\u2014eight U.S. locations, December 2020-March 2021.","volume":"70","author":"Thompson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi220221r5","first-page":"28","article-title":"Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection.","volume":"3","author":"Puranik","year":"2022","journal-title":"Med (N Y)"},{"issue":"7","key":"zoi220221r6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of COVID-19 vaccines against the B.1.617.2 (Delta) variant.","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"issue":"15","key":"zoi220221r7","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1056\/NEJMoa2110362","article-title":"Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings.","volume":"385","author":"Thompson","year":"2021","journal-title":"N Engl J Med"},{"issue":"37","key":"zoi220221r8","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.15585\/mmwr.mm7037e2","article-title":"Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance\u2014nine states, June-August 2021.","volume":"70","author":"Grannis","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"38","key":"zoi220221r9","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.15585\/mmwr.mm7038e1","article-title":"Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions\u2013United States, March-August 2021.","volume":"70","author":"Self","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"15","key":"zoi220221r12","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa2114255","article-title":"Protection of BNT162b2 vaccine booster against COVID-19 in Israel.","volume":"385","author":"Bar-On","year":"2021","journal-title":"N Engl J Med"},{"issue":"11","key":"zoi220221r14","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat Med"},{"issue":"23","key":"zoi220221r16","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1056\/NEJMoa2109730","article-title":"Myocarditis after BNT162b2 mRNA vaccine against COVID-19 in Israel.","volume":"385","author":"Mevorach","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi220221r17","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","article-title":"Myocarditis after COVID-19 vaccination in a large health care organization.","volume":"385","author":"Witberg","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi220221r18","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1056\/NEJMc2105869","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination.","volume":"384","author":"Muir","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"zoi220221r19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1056\/NEJMc2106075","article-title":"Thrombotic thrombocytopenia after Ad26.COV2.S vaccination\u2014response from the manufacturer.","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi220221r20","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi220221r21","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination.","volume":"384","author":"Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"zoi220221r22","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","article-title":"Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination.","volume":"384","author":"Scully","year":"2021","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi220221r23","first-page":"965","article-title":"Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines.","volume":"2","author":"McMurry","year":"2021","journal-title":"Med (N Y)"},{"issue":"39","key":"zoi220221r26","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.15585\/mmwr.mm7039e4","article-title":"Safety monitoring of an additional dose of COVID-19 vaccine United States, August 12-September 19, 2021.","volume":"70","author":"Hause","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"zoi220221r31","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.58227","article-title":"Augmented curation of clinical notes from a massive EHR system reveals symptoms of impending COVID-19 diagnosis.","volume":"9","author":"Wagner","year":"2020","journal-title":"Elife"},{"issue":"1","key":"zoi220221r32","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41746-021-00484-7","article-title":"Mapping each pre-existing condition\u2019s association to short-term and long-term COVID-19 complications.","volume":"4","author":"Venkatakrishnan","year":"2021","journal-title":"NPJ Digit Med"},{"issue":"1","key":"zoi220221r33","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data.","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care"},{"issue":"6","key":"zoi220221r34","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MLR.0b013e31819432e5","article-title":"A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data.","volume":"47","author":"van Walraven","year":"2009","journal-title":"Med Care"},{"issue":"7872","key":"zoi220221r36","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41586-021-03791-x","article-title":"Systems vaccinology of the BNT162b2 mRNA vaccine in humans.","volume":"596","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"zoi220221r10","doi-asserted-by":"crossref","unstructured":"Puranik? A, Lenehan? PJ, O\u2019Horo? JC,  . Durability analysis of the highly effective BNT162b2 vaccine against COVID-19.? bioRxiv. Preprint posted online September 7, 2021. doi:10.1101\/2021.09.04.21263115","DOI":"10.1101\/2021.09.04.21263115"},{"key":"zoi220221r11","doi-asserted-by":"crossref","unstructured":"Israel? A, Merzon E, Sh\u00e4ffer AA, . Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort.? medRxiv. Preprint posted online August 5, 2021. doi:10.1101\/2021.08.03.21261496","DOI":"10.1101\/2021.08.03.21261496"},{"key":"zoi220221r13","unstructured":"Pfizer. Pfizer and BioNTech announce phase 3 trial data showing high efficacy of a booster dose of their COVID-19 vaccine. Accessed March 8, 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-announce-phase-3-trial-data-showing"},{"key":"zoi220221r15","unstructured":"Centers for Disease Control and Prevention. Possible Side Effects After Getting a COVID-19 Vaccine. Accessed March 8, 2022. https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/vaccines\/expect\/after.html"},{"key":"zoi220221r24","unstructured":"Pfizer. Pfizer and BioNTech initiate rolling submission of supplemental biologics license application to U.S. FDA for booster dose of Comirnaty in individuals 16 and older. Accessed March 8, 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-initiate-rolling-submission"},{"key":"zoi220221r25","doi-asserted-by":"crossref","unstructured":"Mofaz? M, Ychezkel? M, Guan? G, . Self-reported and physiological reactions to the third BNT162b2 mRNA COVID-19 (booster) vaccine dose.? bioRxiv. Preprint posted online September 22, 2021. doi:10.1101\/2021.09.15.21263633","DOI":"10.1101\/2021.09.15.21263633"},{"key":"zoi220221r27","unstructured":"Mayo Clinic. Institutional review board (IRB). Accessed March 9, 2022. https:\/\/www.mayo.edu\/research\/institutional-review-board\/overview"},{"key":"zoi220221r28","unstructured":"US Census Bureau. About the topic of race. Accessed March 18, 2022. https:\/\/www.census.gov\/topics\/population\/race\/about.html"},{"key":"zoi220221r29","unstructured":"US Census Bureau. About the Hispanic population and it's origin. Accessed March 18, 2022. https:\/\/www.census.gov\/topics\/population\/hispanic-origin\/about.html"},{"key":"zoi220221r30","unstructured":"Devlin? J, Chang? MW, Lee? K, and Toutanova? K. BERT: pre-training of deep bidirectional transformers for language understanding. arXiv.org. Accessed March 8, 2022. https:\/\/arxiv.org\/abs\/1810.04805"},{"key":"zoi220221r35","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC\/DDD index. Accessed March 8, 2022. https:\/\/www.whocc.no\/atc_ddd_index\/?code=L04A&showdescription=no"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2791034\/niesen_2022_oi_220221_1649278353.08675.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:01:04Z","timestamp":1649934064000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2791034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.7038","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.11.05.21265961","asserted-by":"object"}]},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}